13 results about "PRIMARY BILIARY ATRESIA" patented technology

The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

The present application relates to the technical field of vascular interventional treatment instruments, and discloses a system and method for the selective laser ablation of restenosis after the treatment of Budd-Chiari syndrome, comprising a controller, a pulse emission module and a reference element built into a catheter, the system is based on the reference element for periodic self-calibration, collects and processes the associated photoacoustic signals to identify the tissue type, and then realizes the selective ablation of the diseased tissue and the boundary self-stop when the healthy tissue is touched. The present application converts the traditional open-loop energy delivery into a closed-loop self-control process with real-time information interaction capability, so that the ablation operation end can in-situ perceive the tissue boundary and realize autonomous stop, thereby avoiding the problem of damaging the healthy tissue due to uncontrollable energy application, improving the safety of the operation, and having the advantages of high precision, few complications, repeatable treatment and the like.

The present application relates to the field of medical immunology technology, and more particularly to biomarkers and their application in the assessment of liver damage in end-stage liver disease. In the present application, the proportion of CCR7+CD8+ T cells in CD8+ T cells is used as a marker for the assessment of liver damage in end-stage liver disease, which can reflect the liver immune status of end-stage liver disease, especially the assessment of the degree of liver damage, has high specificity and sensitivity, and provides a scientific basis for the development of clinical individualized treatment plan, and has good practical application value. At the same time, while reflecting the liver damage process of the patient, it can also reflect the immune status of the patient's liver, and can provide certain theoretical basis for slowing down the disease progression of subsequent biliary atresia and other end-stage liver disease patients with liver damage.

The invention relates to the technical field of vascular interventional therapy instruments, and discloses an excimer laser ablation system and method for restenosis after Budd-Chiari syndrome interventional therapy, the excimer laser ablation system comprises a controller, a pulse transmitting module and a reference element arranged in a catheter, and the system performs periodic self-calibration based on the reference element; according to the method, associated photoacoustic signals are collected and processed to identify tissue types, selective ablation of lesion tissues and boundary self-stop when healthy tissues are touched are further achieved, traditional open-loop energy delivery is converted into a closed-loop self-control process with real-time information interaction capacity, and the method has the advantages of being simple in structure, convenient to operate and high in practicability. The ablation operation tail end can sense the tissue boundary in situ and achieve automatic stopping, so that the problem that healthy tissue is damaged due to uncontrollable energy application is solved, the safety of an operation is improved, and the advantages of being high in precision, few in complication, capable of achieving repeated treatment and the like are achieved.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The invention belongs to the technical field of biological medicines, and particularly relates to application of PF-06260933 in preparation of a medicine for treating biliary atresia. The invention provides an application of an HGK inhibitor PF-06260933 in preparation of a medicine for treating biliary atresia. A BA organ and biliary duct ligation (BDL) induced mouse model is constructed, PF-06260933 is adopted to inhibit pro-inflammatory and pro-fibrosis related signal channels of biliary duct epithelial cells, and the improvement effect of PF-06260933 on biliary duct atresia pathological phenotypes is observed. Results show that the PF-06260933 treatment not only can significantly improve inflammatory fibrosis phenotypes of BA organs, but also can significantly improve mouse liver functions, relieve liver inflammation and fibrosis, and effectively reverse pathogenic activation phenotypes of bile duct epithelial cells. Compared with the traditional niberous surgery or non-specific immunosuppression therapy, the method has the advantages of remarkable progress and huge clinical application potential.

The invention discloses a preparation method and application of exosome-loaded Cas13d-RNP, and belongs to the technical field of biliary atresia research. The method comprises the following steps: extracting exosomes: culturing human bile duct cells H69 in a DMEM / F12 culture medium until the cell density reaches 90%, collecting supernatant of the culture medium, and extracting the exosomes by an ultracentrifugation method; cas13d-RNP loading: the Cas13d protein and crRNA are mixed for 15 minutes at the room temperature, Cas13d-RNP is obtained, the exosome and the Cas13d-RNP are mixed, and the Cas13d-RNP is loaded into the exosome in a circulating freezing and thawing mode. According to the invention, Cas13d-RNP is accurately delivered through the exosome vector, specific targeting is carried out on bile duct cell CTGF mRNA, and expression of fibrosis-related factors in bile duct cells is significantly reduced. Compared with traditional medicine treatment, bile duct reaction and fibrosis processes can be more effectively inhibited. As a natural vector, the exosome has the advantages of low immunogenicity and high delivery efficiency, and immunoreactions possibly caused by a traditional virus vector are reduced.

The invention belongs to the technical field of biological medicine, and particularly relates to a biliary atresia differential diagnosis and prognosis marker and application thereof. The invention provides the application of the KRT17 expression level as a biliary atresia differential diagnosis and prognostic marker for the first time. KRT17 as a single marker has a relatively high diagnostic value (AUC = 0.880) for BA, the efficiency of KRT17 is superior to all conventional clinical liver function indexes, and when KRT17 is combined with alanine aminotransferase for use, the diagnostic accuracy can be further improved to AUC = 0.904, the KRT17 and CX3CL1 are optimally combined, and the AUC value is as high as 0.938. According to the technology, KRT17 is used as a novel biliary atresia differential diagnosis marker, the defects of an existing differential diagnosis system can be made up to a certain degree, the KRT17 is specifically and highly expressed in biliary atresia liver bile duct epithelial cells, normal control and disease control are not expressed, and therefore more accurate differential diagnosis can be provided clinically.

The present invention proposes an intelligent biliary atresia recognition model based on multimodal medical data, which belongs to the field of data processing. In the data preprocessing stage, the key position information of the multimodal data is acquired; in the feature extraction stage, the visual image feature encoding and numerical data feature encoding are used to provide a basis for subsequent modal fusion; in the modal fusion stage, through multi-level fine-grained fusion, the image features are first innovatively fused using the masked self-attention mechanism for fine-grained fusion, and then multimodal fusion is performed at the overall level, effectively improving the fusion effect under modality loss, thereby effectively capturing the key features between and within the modalities and interactively fusing them, providing a basis for high-precision prediction. In order to improve the model training efficiency and prediction accuracy, a multi-loss training method is used, which not only incorporates the multimodal fusion feature loss, but also adds a certain proportion of the loss of single-modal calculation. Finally, the intelligent recognition and prediction of biliary atresia are performed by training the model weights.

The invention belongs to the technical field of biological medicines, and particularly relates to application of parinumod in preparation of a medicine for treating biliary atresia. The invention discovers the treatment application of the S100A8 / A9 inhibitor in biliary atresia for the first time. The method comprises the following steps: inducing the formation of BA by intraperitoneal injection of RRV within 24 hours after a BALB / c newborn mouse is born, and after the RRV is injected from the intraperitoneal cavity, from the second day, injecting an S100A8 / A9 inhibitor Paquinimod (dosage: 50 mg / kg) into the intraperitoneal cavity of the mouse once every other day until the twelfth day. It can be observed that the survival time of the BA mouse treated by Paquinimod is prolonged, the jaundice symptom is relieved, the liver function index is obviously improved, and the infiltration number of inflammatory cells around the hepatic bile duct is obviously reduced. The invention provides a new potential target and a treatment strategy for treatment of BA.

This invention belongs to the field of biomedical technology, specifically relating to the application of spermine in the preparation of drugs for treating biliary atresia. This invention is the first to verify, through animal experiments (RRV mouse model), that spermine has a clear therapeutic effect on biliary atresia, achieving common bile duct recanalization and significantly reducing liver inflammation. Spermine itself possesses multiple functions including antioxidant, anti-inflammatory, and direct JAK1 inhibition, potentially working synergistically through multiple mechanisms such as mitigating initial damage and regulating immune responses, providing a more comprehensive pathological intervention than single-target inhibitors. Furthermore, spermine, as a known compound, has low production costs, and its application will greatly improve the accessibility of treatment.

Disclosed in the present invention are a metabolite combination for evaluating the risk of biliary atresia in neonates and a use thereof. The metabolite combination comprises one or more of the following: hyocholic acid, pyroglutamic acid, α-aminobutyric acid, 3-methyl-2-oxovaleric acid and monoconjugated bilirubin, and the metabolite combination cannot only contain one metabolite of monoconjugated bilirubin. The metabolite combination has relatively high correlation with biliary atresia, and has high accuracy, sensitivity and specificity for evaluation of the risk of biliary atresia in neonates.

The invention provides application of a medicine taking FZD6 as a target spot in preparation of a medicine for treating biliary atresia, and relates to the technical field of biological medicine. The research of the inventor finds that the FZD6 gene can play a causal role in BA through gene regulation and control. Enrichment analysis shows that the gene participates in various signal pathways. Through immune infiltration analysis, difference analysis and key immune cell-gene correlation analysis, it is found that FZD6 is significantly related to most BA-related immune cells. Immunohistochemical analysis proves that the FZD6 is obviously expressed in bile duct epithelial cells of a BA patient, so that the FZD6 can be used for BA diagnosis according to the expression level of the FZD6. Drug prediction and molecular docking analysis show that dexamethasone and schisandrin N have very strong binding affinity with FZD6 and are potential therapeutic drugs, and the FZD6 gene can be used as a potential drug therapeutic target of BA.